Immunai
Healthcare Software · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
430 E 29th St, New York City, New York, ...Website
www.immunai.comRevenue
$29.4 MillionIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
2
3
2
2
About Immunai
Founded in 2018 and based in New York City, New York, Immunai is a software developer that offers an AI platform for analyzing the human immune system.Explore more
Immunai Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunai your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Immunai launches new products
Check if Immunai has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Immunai
Immunai, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Immunai is spiking on competitors!
Click to see if Immunai had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Immunai has new funding data
Earning: See what the market has to say on Immunai recently announced quarterly report
Recommended Actions
Find VP level buyers at Immunai
Find 3 more new buyers
Compare Similar Companies to Immunai
Compare insights from companies similar to Immunai, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunai is experiencing very low activity levels compared to other companies in the Software sector.
What does this means?
Immunai is drawing exceptional interest within the Software industry, suggesting notable developments or strong market momentum, learn more about Immunai.
Immunai financials insights
Gather financial insights about Immunai, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$20M
2021
Series A
$60M
Series B
$215M
Immunai Tech Stack
A closer look at the technologies used by Immunai
See more technologies
Most Recent Scoops
Open Position
Person-Based
Pharmaceuticals
Hiring Plans
Immunai has more open roles in Finance than it has had at any time in the past 12 months.
Hiring Plans
Person-Based
Partnership, Medical Research, Pharmaceuticals
Hiring Plans
Hiring Plans
Immunai News & Media
AstraZeneca extends AI immuno-oncology R&D pact with Immunai - Fierce Biotech
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its artificial-intelligence-powered immune cell atlas in the design of the drugmake | Immunai has been building a digital map of the immune system by charting each cell type’s function and their interactions with the body and various diseases.Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed/Refractory Neuroblastoma
NEW YORK--(BUSINESS WIRE)--Investigators from Baylor College of Medicine (BCM) in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify BTG1 as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. The study was published today in Nature Medicine. As part of this collaboration, Immunai leveraged its advanced multi-omics platform to analyze clinical samplesImmunai raises USD 215 million for its drug discovery platform | KrASIA
Immunai raises USD 215 million for its drug discovery platform. Immunai uses analytics and machine learning to improve the efficiency of immunotherapies.From Atlas to Actuary: Immunai Expands Immune Mapping with $215M in Series B
Immunai says its ambitious goals of mapping the entire immune system and continuing its rapid growth will be made easier by the $215 million in financing the company has completed—a Series B round that has more than doubled the total capital raised by the three-year-old company.
Read more news
Top Healthcare Software Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immunai
Sign Up For FreeTo access detailed company insights
Founded in 2018 and based in New York City, New York, Immunai is a software developer that offers an AI platform for analyzing the human immune system.... Read More
